Akademik Veri Yönetim Sistemi
Journal of Advanced Research in Health Sciences, cilt.7, sa.1, ss.32-36, 2024 (Hakemli Dergi)
ABSTRACT
Objectives: The molecular response to tyrosine kinase inhibitors in
chronic myeloid leukemia (CML) is monitored by quantitative detection of
BCR/ABL transcripts. After the initiation of the treatment, patients are
followed-up with molecular analysis at three-month intervals. Early
molecular response (EMR) is considered achieved when the BCR/ABL
international scale (IS) is 10% or below in the three-month follow-up after
treatment. This response, which has been reported to have a strong
prognostic significance in CML patients, is associated with favorable longterm outcomes. However, the three-month follow-up period may be too
long in terms of disease progression and treatment management for
patients who fail to achieve EMR. Therefore, additional biomarkers that
can predict the prognosis are needed.
Material and Methods: This study investigated the relationship between
serine protease 57 (PRSS57) gene expression, and EMR. The PRSS57 gene
expression in 20 CML patients was determined by the quantitative reverse
transcriptase polymerase chain reaction (qRT-PCR) method and its
relationship with EMR was analyzed.
Results: The PRSS57 gene expression was found to be significantly higher
in patients who failed EMR (p=0.002) and positively correlated with BCR/
ABL IS value (r=0.567, p=0.009). Our results also revealed that the PRSS57
gene expression was decreased in the post-treatment follow-up sample
when compared with the diagnostic sample (p=0.000).
Conclusion: These findings indicate that the PRSS57 gene expression in
diagnosis may be useful for predicting patients at high risk of EMR failure.
Keywords: CML, early molecular response, PRSS57